

**SOPHARMA AD**  
**INDIVIDUAL STATEMENT OF COMPREHENSIVE INCOME**  
**for the period ended 31 March 2019**

	Notes	2019 BGN'000	2018 ** BGN'000 <i>recalculated*</i>
<b>Revenues</b>	3	52,174	53,291
Other operating revenue/(loss), net	4	920	478
Change of available stock of finished goods and work in progress		3,337	6,176
Materials	5	(19,157)	(20,552)
External services	6	(7,789)	(8,987)
Emoloyees	7	(12,316)	(11,721)
Amortization	13,14	(4,540)	(4,484)
Other operating expenses	8,9	(496)	(714)
<b>Operating profit</b>		<b>12,133</b>	<b>13,487</b>
Financial income	10	2,462	393
Financial expenses	11	(309)	(369)
<b>Financial income/(expenses), net</b>		<b>2,153</b>	<b>24</b>
<b>Profit before tax</b>		<b>14,286</b>	<b>13,511</b>
Profit tax		(1,392)	(1,097)
<b>Net profit for the year</b>		<b>12,894</b>	<b>12,414</b>
<b>Other components of the total income:</b>			
<i>Items that will not be reclassified to profit or loss:</i>			
Net change in the fair value of other long-term equity investments	18	55	43
<b>Other comprehensive income for the period net of tax</b>	12	<b>55</b>	<b>43</b>
<b>TOTAL COMPREHENSIVE INCOME FOR THE YEAR</b>		<b>12,949</b>	<b>12,457</b>
Earnings per share	26	<b>0.10</b>	<b>0.10</b>

*The notes on pages 5 to 115 are an integral part of the present financial statement.*

**Executive Director:**

**Ognian Donev, PhD**

**Finance Director:**

**Boris Borisov**

**Chief Accountant (preparer):**

**Iordanka Petkova**

\* *United indicators (Note 2.3)*

\*\* *Modified retrospective application of IFRS 16 (Note 30)*